Ocular Surface Disease

BRS Analytical Service, LLC, an independent contract testing laboratory, initiated the recall because of possible concerns about product quality and safety linked to the manufacturing process. An FDA audit revealed serious manufacturing violations of Current Good Manufacturing Practice.

Identifying allergens or irritants can be challenging, but a few strategies can help patients find relief.

Inflammation is both a cause and consequence of dry eye disease.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment.

An overview of prescription medications available for DED.

Cationic emulsion drops are characterized by their ability to retain cyclosporine A on the ocular surface.

The dynamic muscle stimulation device is a noninvasive option for patients experiencing lower lid laxity and impaired blinking.

Annual reports of the occurrence of adverse effects associated with the use of cosmetics increased from 2006 to 2018, then decreased from 2018 to 2021.

Preservatives may disrupt the ocular surface, contributing to poor adherence.

This year was brimming with advancements in eye care.

According to Mile Brujic, OD, FAAO, low-level light therapy (LLLT) and intense pulsed light have demonstrated tremendous benefits for his patients.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

A few optometrists share which innovations in optometry they were most excited about in 2024.

Inside the role of blepharitis in ocular surface disease and effective management strategies.

All 6 biomarkers in the study demonstrated improvement with the treatment of lifitegrast, according to Thimons.

In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.

The retrospective study investigated and analyzed the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.

Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been recommending the NutriTears supplement to their dry eye patients.

David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.

Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.

Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.

What we know and what we do not know…yet.

Lisa Hornick, OD, MBA, FAAO, outlines key findings from the report on the impacts of healthy cosmetic habits and reducing digital eye strain.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, tackled new and exciting ways to tackle meibomian gland dysfunction alongside fellow ocular surface specialist Rana Taji, OD, MSc, FAAO, at AAOpt 2024.

Dr. Justin Schweitzer's 2024 AAOpt talk will cover the latest advancements in ocular drug delivery, including topical, implant, and contact lens-based methods that can improve patient quality of life, adherence, and financial burden.

The lipid-containing lubricating drop established noninferiority in comfort when compared to non-lipid drops, and the lipid-containing group also exhibited statistically significant improvements in visual quality at both day 7 and day 30, highlighting the potential benefits of this formulation for patients.